Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Septerna, Inc.

Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
Septerna to Present at TD Cowen 45th Annual Health Care Conference
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
Septerna Prices Upsized Initial Public Offering
From Septerna, Inc.
Via GlobeNewswire
Septerna Presents New Preclinical Data at ASBMR 2024 Highlighting Therapeutic Potential of Oral Small Molecule Parathyroid Hormone 1 Receptor (PTH1R) Agonists for Hypoparathyroidism
From Septerna, Inc.
Via Business Wire
Septerna Marks Transition to a Clinical-Stage Company with Appointments of Industry Veterans in Key Drug Development Roles
From Septerna, Inc.
Via Business Wire
Septerna Announces Novel GPCR-targeted Program Acquired by Vertex
From Septerna, Inc.
Via Business Wire
Septerna Announces the Formation of a Cross-Functional Scientific and Drug Discovery Advisory Board
From Septerna, Inc.
Via Business Wire
Septerna Appoints Jeffrey Finer, MD, PhD, as Chief Executive Officer
From Septerna, Inc.
Via Business Wire
Septerna Launches With $100 Million Series A Financing to Expand the Frontier of GPCR-Targeted Medicines Using the Native Complex™ Platform
From Septerna, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.